Replacing adenoviral vector HVR1 with a malaria B cell epitope improves immunogenicity and circumvents preexisting immunity to adenovirus in mice

Journal of Clinical Investigation

Volumn 120, Issue 10, 2010, Pages 3688-3701

  Shiratsuchi, Takayuki ^a   Rai, Urvashi ^a   Krause, Anja ^b   Worgall, Stefan ^b   Tsuji, Moriya ^a  

^a AARON DIAMOND AIDS RESEARCH CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CIRCUMSPOROZOITE PROTEIN; GAMMA INTERFERON; MALARIA VACCINE; CAPSID PROTEIN; CIRCUMSPOROZOITE PROTEIN, PROTOZOAN; EPITOPE; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOGENICITY; IMMUNOGLOBULIN VARIABLE REGION; MALARIA; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; PLASMODIUM YOELII; PRIORITY JOURNAL; SILVER STAINING; TRANSGENE; VACCINATION; VIRUS CAPSID; VIRUS NEUTRALIZATION; WESTERN BLOTTING; WILD TYPE; ADENOVIRIDAE; ANIMAL; BAGG ALBINO MOUSE; FEMALE; GENE VECTOR; GENETICS; HUMAN; IMMUNOLOGY; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; TUMOR CELL LINE;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, PROTOZOAN; BASE SEQUENCE; CAPSID PROTEINS; CELL LINE, TUMOR; EPITOPES, B-LYMPHOCYTE; FEMALE; GENETIC VECTORS; HUMANS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PLASMODIUM YOELII; PROTOZOAN PROTEINS;

EID: 77957841735     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI39812     Document Type: Article

References (32)

1. World Health Organization. World Malaria Report 2005. http://rbm.who.int/wmr2005/. Accessed May 13, 2010.
2. Nussenzweig RS, Vanderberg J, Most H, Orton C. Protective immunity produced by the injection of x-irradiated sporozoites of plasmodium berghei. Nature. 1967;216(5111):160-162.
3. Gwadz R, Cochrane AH, Nussenzweig V, Nussenzweig RS. Preliminary studies on vaccination of rhesus monkeys with irradiated sporozoites of Plasmodium knowlesi and characterization of surface antigens of these parasites. Bull World Health Organ. 1979;57 suppl 1:165-173. (Pubitemid 10110809)
4. Clyde DF, Most H, McCarth VC, Vanderberg JP. Immunization of man against sporozite-induced falciparum malaria. Am J Med Sci. 1973;266(3):169-177.
5. Edelman R, et al. Long-term persistence of sterile immunity in a volunteer immunized with X-irradiated Plasmodium falciparum sporozoites. J Infect Dis. 1993;168(4):1066-1070.
6. Nussenzweig V, Nussenzweig RS. Circumsporozoite proteins of malaria parasites. Cell. 1985;42(2):401-403.
7. Nardin EH, et al. Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax. J Exp Med. 1982;156(1):20-30.
8. Tsuji M, Zavala F. T cells as mediators of protective immunity against liver stages of Plasmodium. Trends Parasitol. 2003;19(2):88-93. (Pubitemid 36173891)
9. Rodrigues EG, Zavala F, Eichinger D, Wilson JM, Tsuji M. Single immunizing dose of recombinant adenovirus efficiently induces CD8+ T cell-mediated protective immunity against malaria. J Immunol. 1997;158(3):1268-1274.
10. Anderson RJ, et al. Enhanced CD8+ T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus. J Immunol. 2004;172(5):3094-3100.
11. Bruña-Romero O, González-Aseguinolaza G, Hafalla JC, Tsuji M, Nussenzweig RS. Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen. Proc Natl Acad Sci U S A. 2001;98(20):11491-11496.
12. Tao D, Barba-Spaeth G, Rai U, Nussenzweig V, Rice CM, Nussenzweig RS. Yellow fever 17D as a vaccine vector for microbial CTL epitopes: protection in a rodent malaria model. J Exp Med. 2005;201(2):201-209.
13. Worgall S, et al. Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid. J Clin Invest. 2005;115(5):1281-1289.
14. McConnell MJ, Danthinne X, Imperiale MJ. Characterization of a permissive epitope insertion site in adenovirus hexon. J Virol. 2006;80(11):5361-5370.
15. Krause A, et al. Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity. J Virol. 2006;80(11):5523-5530.
16. Worgall S, Krause A, Qiu J, Joh J, Hackett NR, Crystal RG. Protective immunity to pseudomonas aeruginosa induced with a capsid-modified adenovirus expressing P. aeruginosa OprF. J Virol. 2007;81(24):13801-13808. (Pubitemid 350247873)
17. Ophorst OJ, et al. Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice. Infect Immun. 2006;74(1):313-320.
18. Abbink P, et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol. 2007;81(9):4654-4663.
19. Wu H, Dmitriev I, Kashentseva E, Seki T, Wang M, Curiel DT. Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon. J Virol. 2002;76(24):12775-12782.
20. Roberts DM, et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature. 2006;441(7090):239-243.
21. Bergelson JM, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science. 1997;275(5304):1320-1323.
22. Silvie O, et al. Expression of human CD81 differently affects host cell susceptibility to malaria sporozoites depending on the Plasmodium species. Cell Microbiol. 2006;8(7):1134-1146.
23. Tatsis N, Ertl HC. Adenoviruses as vaccine vectors. Mol Ther. 2004;10(4):616-629.
24. Kalyuzhniy O, et al. Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc Natl Acad Sci U S A. 2008;105(14):5483- 5488. (Pubitemid 351753889)
25. Hsu C, Boysen M, Gritton LD, Frosst PD, Nemerow GR, Von Seggern DJ. In vitro dendritic cell infection by pseudotyped adenoviral vectors does not correlate with their in vivo immunogenicity. Virology. 2005;332(1):1-7.
26. Charoenvit Y, et al. Monoclonal, but not polyclonal, antibodies protect against Plasmodium yoelii sporozoites. J Immunol. 1991;146(3):1020-1025.
27. Wang R, et al. Induction of protective polyclonal antibodies by immunization with a Plasmodium yoelii circumsporozoite protein multiple antigen peptide vaccine. J Immunol. 1995;154(6):2784-2793.
28. Pichla-Gollon SL, et al. Structure-based identification of a major neutralizing site in an adenovirus hexon. J Virol. 2007;81(4):1680-1689.
29. Abe S, et al. Adenovirus type 5 with modified hexons induces robust transgene-specific immune responses in mice with pre-existing immunity against adenovirus type 5. J Gene Med. 2009;11(7):570-579.
30. Grote A, et al. JCat: a novel tool to adapt codon usage of a target gene to its potential expression host. Nucleic Acids Res. 2005;33(Web Server issue):W526-W531.
31. Calvo-Calle JM, Oliveira GA, Watta CO, Soverow J, Parra-Lopez C, Nardin EH. A linear peptide containing minimal T- and B-cell epitopes of Plasmodium falciparum circumsporozoite protein elicits protection against transgenic sporozoite challenge. Infect Immun. 2006;74(12):6929-6939.
32. Mack SR, Vanderberg JP, Nawrot R. Column separation of Plasmodium berghei sporozoites. J Parasitol. 1978;64(1):166-168. (Pubitemid 8312840)